Cancers (Nov 2022)

Clinical Score to Predict Recurrence in Patients with Stage II and Stage III Colon Cancer

  • David Viñal,
  • Sergio Martinez-Recio,
  • Daniel Martinez-Perez,
  • Iciar Ruiz-Gutierrez,
  • Diego Jimenez-Bou,
  • Jesús Peña-Lopez,
  • Maria Alameda-Guijarro,
  • Gema Martin-Montalvo,
  • Antonio Rueda-Lara,
  • Laura Gutierrez-Sainz,
  • Maria Elena Palacios,
  • Ana Belén Custodio,
  • Ismael Ghanem,
  • Jaime Feliu,
  • Nuria Rodríguez-Salas

DOI
https://doi.org/10.3390/cancers14235891
Journal volume & issue
Vol. 14, no. 23
p. 5891

Abstract

Read online

Background: The prognosis of patients with stage II and stage III colon cancer is heterogeneous. Clinical and pathological characteristics, such as tumor budding, may help to further refine the recurrence risk. Methods: We included all the patients with localized colon cancer at Hospital Universitario La Paz from October 2016 to October 2021. We built a prognostic score for recurrence in the training cohort based on multivariate cox regression analysis and categorized the patients into two risk groups. Results: A total of 440 patients were included in the training cohort. After a median follow-up of 45 months, 81 (18%) patients had a first tumor recurrence. T4, N2, and high tumor budding remained with a p value p < 0.045)). The results were confirmed in the validation cohort. Conclusions: In our study, we built a simple score to predict tumor recurrence based on T4, N2, and high tumor budding. Patients in the low-risk group, that comprised 44% of the cohort, had an excellent prognosis.

Keywords